BG64472B1 - Използване на сибутраминови аналози за понижаване нивата на липидите - Google Patents

Използване на сибутраминови аналози за понижаване нивата на липидите Download PDF

Info

Publication number
BG64472B1
BG64472B1 BG103249A BG10324999A BG64472B1 BG 64472 B1 BG64472 B1 BG 64472B1 BG 103249 A BG103249 A BG 103249A BG 10324999 A BG10324999 A BG 10324999A BG 64472 B1 BG64472 B1 BG 64472B1
Authority
BG
Bulgaria
Prior art keywords
formula
compound
medicament
cyclobutyl
dimethyl
Prior art date
Application number
BG103249A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103249A (en
Inventor
Finian Kelly
Paul Jones
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of BG103249A publication Critical patent/BG103249A/xx
Publication of BG64472B1 publication Critical patent/BG64472B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analogue/Digital Conversion (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG103249A 1996-09-25 1999-03-15 Използване на сибутраминови аналози за понижаване нивата на липидите BG64472B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment

Publications (2)

Publication Number Publication Date
BG103249A BG103249A (en) 1999-09-30
BG64472B1 true BG64472B1 (bg) 2005-04-30

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103249A BG64472B1 (bg) 1996-09-25 1999-03-15 Използване на сибутраминови аналози за понижаване нивата на липидите

Country Status (26)

Country Link
US (1) US6187820B1 (zh)
EP (1) EP0973511B1 (zh)
JP (1) JP4143126B2 (zh)
KR (1) KR100573333B1 (zh)
CN (1) CN1173696C (zh)
AT (1) ATE239459T1 (zh)
AU (1) AU724645B2 (zh)
BG (1) BG64472B1 (zh)
BR (1) BR9711411A (zh)
CA (1) CA2266378C (zh)
CZ (1) CZ291879B6 (zh)
DE (1) DE69721833T2 (zh)
DK (1) DK0973511T3 (zh)
ES (1) ES2199354T3 (zh)
GB (1) GB9619961D0 (zh)
HU (1) HU224711B1 (zh)
IL (1) IL128820A (zh)
NO (1) NO991424D0 (zh)
NZ (1) NZ334550A (zh)
PL (1) PL190017B1 (zh)
PT (1) PT973511E (zh)
RU (1) RU2197959C2 (zh)
SK (1) SK284282B6 (zh)
TR (1) TR199900648T2 (zh)
UA (1) UA63916C2 (zh)
WO (1) WO1998013034A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6433020B1 (en) * 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
WO2004096202A1 (en) * 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
JP2008526836A (ja) 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080818A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098602A (en) * 1981-04-06 1982-11-24 Boots Co Plc Therapeutic agents
EP0230742A1 (en) * 1985-12-17 1987-08-05 The Boots Company PLC N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
EP0397831A1 (en) * 1988-11-29 1990-11-22 Boots Co Plc TREATMENT OF OBESITAS.
WO1995020949A1 (en) * 1994-02-03 1995-08-10 Boots Pharmaceuticals, Inc. Improving glucose tolerance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098602A (en) * 1981-04-06 1982-11-24 Boots Co Plc Therapeutic agents
EP0230742A1 (en) * 1985-12-17 1987-08-05 The Boots Company PLC N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
EP0397831A1 (en) * 1988-11-29 1990-11-22 Boots Co Plc TREATMENT OF OBESITAS.
WO1995020949A1 (en) * 1994-02-03 1995-08-10 Boots Pharmaceuticals, Inc. Improving glucose tolerance

Also Published As

Publication number Publication date
HU224711B1 (en) 2006-01-30
EP0973511A1 (en) 2000-01-26
PL190017B1 (pl) 2005-10-31
UA63916C2 (uk) 2004-02-16
CA2266378C (en) 2007-02-13
US6187820B1 (en) 2001-02-13
CN1231605A (zh) 1999-10-13
HUP9903823A3 (en) 2000-07-28
HUP9903823A2 (hu) 2000-06-28
DE69721833T2 (de) 2003-12-24
PT973511E (pt) 2003-08-29
PL332367A1 (en) 1999-09-13
CZ93299A3 (cs) 2000-07-12
CA2266378A1 (en) 1998-04-02
SK32099A3 (en) 1999-12-10
BG103249A (en) 1999-09-30
KR20000048567A (ko) 2000-07-25
AU724645B2 (en) 2000-09-28
ES2199354T3 (es) 2004-02-16
BR9711411A (pt) 1999-08-17
AU4774197A (en) 1998-04-17
IL128820A (en) 2001-10-31
TR199900648T2 (xx) 1999-06-21
NO991424L (no) 1999-03-24
DK0973511T3 (da) 2003-08-25
GB9619961D0 (en) 1996-11-13
ATE239459T1 (de) 2003-05-15
CN1173696C (zh) 2004-11-03
NZ334550A (en) 2000-09-29
JP4143126B2 (ja) 2008-09-03
JP2001500883A (ja) 2001-01-23
DE69721833D1 (de) 2003-06-12
KR100573333B1 (ko) 2006-04-24
WO1998013034A1 (en) 1998-04-02
EP0973511B1 (en) 2003-05-07
RU2197959C2 (ru) 2003-02-10
NO991424D0 (no) 1999-03-24
CZ291879B6 (cs) 2003-06-18
SK284282B6 (sk) 2004-12-01
IL128820A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
BG64472B1 (bg) Използване на сибутраминови аналози за понижаване нивата на липидите
AU694761B2 (en) Improving glucose tolerance
CA2367666C (en) Method of treating eating disorders
EP1007023B1 (en) 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine derivatives for lowering the uric level in humans
US6376552B1 (en) Treatment of gallstones
WO2000056321A1 (en) Treatment of hyperactivity disorders
WO2000056311A1 (en) Control of metabolism
CA2367041A1 (en) Treatment to lower platelet adhesiveness
US6433020B1 (en) Treatment of cardiovascular disease
CA2366652A1 (en) Treatment of pulmonary hypertension
WO2000056319A1 (en) Treatment of orthostatic hypotension
AU3894400A (en) Treatment of hiatial hernia
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels
CA2367045A1 (en) Treatment of certain cancers associated with weight gain
CA2368416A1 (en) Treatment of gallstones
MXPA99002598A (en) Use of sibutramine analogues to prevent the development of diabetes